Why Biohaven Stock Was Rocking the Market This Week

Biohaven secured a licensing and collaboration deal with SK Biopharmaceuticals valued at up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim, targeting focal epilepsy treatment. The agreement marks a significant milestone for BHVN's neuroscience pipeline and provides substantial non-dilutive capital for development.

Separately, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. The dual catalysts drove BHVN shares up more than 16% for the week.

The SK Biopharmaceuticals partnership provides immediate validation of Biohaven's Kv7 platform technology while the legal victory protects the company's intellectual property portfolio. The $795 million deal structure typically includes upfront payment, development milestones, and commercialization royalties, though specific terms were not disclosed.